Retraction: The Significance of Notch1 Compared with Notch3 in High Metastasis and Poor Overall Survival in Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

1. Retraction: SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT.PloS one · 2024
   Article
2. Retraction: Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression.PloS one · 2024
   Article
3. Retraction: Overexpression of SATB1 Is Associated with Biologic Behavior in Human Renal Cell Carcinoma.PloS one · 2024
   Article

Corrections and comments

• Retraction of
  The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.